Biogen (BIIB)
(Delayed Data from NSDQ)
$173.04 USD
-0.88 (-0.51%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $173.02 -0.02 (-0.01%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$173.04 USD
-0.88 (-0.51%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $173.02 -0.02 (-0.01%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth B Momentum A VGM
Zacks News
Is Biogen (BIIB) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (BIIB) Outperforming Other Medical Stocks This Year?
Has Biogen (BIIB) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (BIIB) Outperforming Other Medical Stocks This Year?
Pain Therapeutics' Shares Rally on Alzheimer's Study Grant
by Zacks Equity Research
Pain Therapeutics (PTIE) receives grant of $3.2 million from National Institutes of Health to support development of its Alzheimer's disease candidate, PTI-125.
Vertex's Cystic Fibrosis Drug Gets FDA Nod for Children
by Zacks Equity Research
Vertex's (VRTX) cystic fibrosis drug, Kalydeco gets FDA approval to treat children aged 12 months to two years
Biotech ETFs in Focus on String of Q2 Earnings Beat
by Sanghamitra Saha
Biotech ETFs draw attention post impressive Q2 results.
PDL BioPharma (PDLI) Q2 Earnings Top, Revenues Slump Y/Y
by Zacks Equity Research
PDL BioPharma's (PDLI) earnings trump estimates in Q2. Lower royalties and license fees cause a significant decline in year-over-year revenues.
S&P 500 Posts 5th Straight Weekly Gain: 5 Great Picks
by Nalak Das
U.S. corporates have so far posted robust results for second-quarter 2018, maintaining the terrific earnings momentum which has begun since the first-quarter 2018.
Zacks.com featured highlights include: Biogen, Thermo Fisher, HCA, Gilead and QUALCOMM
by Zacks Equity Research
Zacks.com featured highlights include: Biogen, Thermo Fisher, HCA, Gilead and QUALCOMM
5 Cheap PEG Stocks Suitable for GARP Investors
by Zacks Equity Research
Although PEG is categorized under value investing, this strategy follows the principles of both growth and value investing.
Is a Beat in Store for Ionis (IONS) This Earnings Season?
by Zacks Equity Research
On Ionis' (IONS) second-quarter 2018 conference call, investor focus will remain on the company's progress with the pipeline candidates as well as royalty revenues earned from Spinraza.
Biotech Stock Roundup: Celgene, Amgen, Vertex Impress in Q2, Gilead's CEO to Exit
by Zacks Equity Research
Impressive second-quarter results by most biotech bigwigs were the key highlights of the week. Most companies upped their guidance.
The Zacks Analyst Blog Highlights: Comcast, United Technologies, Biogen, Mondelez and Valero
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Comcast, United Technologies, Biogen, Mondelez and Valero
Is Biogen (BIIB) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (BIIB) Outperforming Other Medical Stocks This Year?
Top Analyst Reports for Comcast, United Technologies & Biogen
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Comcast (CMCSA), United Technologies (UTX) and Biogen (BIIB).
Drug Stocks to Report Q2 Earnings on Jul 31: PFE, INCY, ECYT
by Zacks Equity Research
Let's see how pharma/biotech stocks are poised ahead of their scheduled results on Jul 31.
Company News For Jul 25, 2018
by Zacks Equity Research
Companies In The News are: HOG,BIIB,LLY,WHR
Drug Stocks to Report Earnings on Jul 26: AMGN, ALXN & More
by Zacks Equity Research
Let's see how these five pharma/biotech stocks are poised ahead of their scheduled results on Jul 26.
Biotech Stock Roundup: Biogen Gains on Q2 Results, Agios Gets FDA Nod For Leukemia Drug
by Zacks Equity Research
The biotech sector is in focus as bigwig Biogen gains on better-than-expected Q2 results. Others like Gilead, Amgen and Celgene too are slated to report shortly.
Bet on These 5 Biotech Stocks as Trump Raises Trade Tensions
by Swarup Gupta
Biotech stocks are largely resilient to trade related disruptions.
Biogen (BIIB) Q2 Earnings & Sales Beat Estimates, Shares Up
by Zacks Equity Research
Biogen (BIIB) beats estimates on both counts in the second quarter. The company's multiple sclerosis drugs' sales up sequentially amid competition.
Biogen (BIIB) Q2 Earnings Beat, Shares Up
by Zacks Equity Research
Biogen (BIIB) beat estimates both for earnings and sales in Q2. The company's oral MS drug Tecfidera sales decreased year over year.
BIIB, LLY Q2 Earnings on Jul 24: Here are the Key Predictions
by Zacks Equity Research
Two large pharma/biotech companies have reported so far, displaying strong sales trend. Let's see how Lilly (LLY) and Biogen (BIIB) are poised ahead of their scheduled results tomorrow.
4 Biotech Bets to Watch as Industry Rebounds in a Month
by Madhu Goel
The biotech sector makes a sharp rise in 30 days post the positive data read out from Biogen's mid-stage Alzheimer's trial on BAN2401. We recommend a few industry players for investors' portfolio boost.
Biogen (BIIB) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
On the Q2 call, investor focus will be on the impact of Roche's newly launched drug, Ocrevus on Biogen's (BIIB) MS franchise and Spinraza's performance
AbbVie Settles With Mylan to Delay Humira Biosimilar in U.S.
by Zacks Equity Research
AbbVie (ABBV) strikes a deal with Mylan to launch its biosimilar Humira in the United States on Jul 31, 2023.